Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

Abstract

Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. Although development of multifocal inflammatory lesions is the underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accumulation of disability that characterises progressive multiple sclerosis seems to result more from diffuse immune mechanisms and neurodegeneration. As a result, the 14 anti-inflammatory drugs that have regulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no efficacy in progressive multiple sclerosis without inflammatory lesion activity. Effective therapies for progressive multiple sclerosis that prevent worsening, reverse damage, and restore function are a major unmet need. In this Series paper we summarise the current status of therapy for progressive multiple sclerosis and outline prospects for the future.

Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom

“…For the majority of other autoimmune disorders, significant strides have taken place to facilitate corticosteroid‐free regimens. Examples include the use of disease‐modifying agents and novel antibodies in diseases such as those utilised in Multiple Sclerosis, Inflammatory Bowel Disease and Rheumatoid Arthritis . These conditions are exemplars of being beneficiaries of the novel therapeutics explosion.…”

All Wrapped Up: Environmental Effects on Myelination

“…Remyelination, a form of myelin plasticity, is impaired in progressive multiple sclerosis (MS), which consequently leads to neurological disability. Cognitive impairment partly derives from a lack of structural and trophic support from OLs to axons, which fail to adequately remyelinate, thereby leading to axonal degeneration and disease progression [77]. In traumatic brain injury (TBI), myelin plasticity and remodeling influence recovery of WM integrity and resynchronization of cortical circuits [78,79].…”

Aluminium in Brain Tissue in Multiple Sclerosis

“…Despite some progress, advances in understanding the pathogenesis of MS remain frustratingly slow [1]. Effective treatments for MS are rare [2,3].…”